Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

Abstract: The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

Abstract: The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments or homologs for the treatment of diseases or disorders involving abnormal angiogenesis and methods of use thereof.

Abstract: Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence: kmviywkag (RZ-3) or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.

Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.

Abstract: A method of treatment for treating, inhibiting, reducing or at least partly preventing respiratory or pulmonary microbial infection or gastrointestinal disorder of tissue of a subject, includes administering to a subject an effective amount of a composition including a polypeptide including thymosin ?4 (TB4), an isoform of TB4, an N-terminal variant of TB4, a C-terminal variant of TB4, LKKTET or a conservative variant thereof, LKKTNT or a conservative variant thereof, TB4 sulfoxide, TB4ala, T?9, T?10, T?11, T?12, T?13, T?14, T?15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ?-actinin, acumentin or a combination thereof, so as to inhibit the infection or disorder.

Abstract: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.

Abstract: The present invention relates to the use of a sulphated polysaccharide in acid form or as a physiologically acceptable salt thereof, selected from the group consisting of inulin sulphate, gellan sulphate, pullulan sulphate, curdlan sulphate, alginiq acid sulphate, laminarin sulphate, and pectin sulphate, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal. Preferably, the sulphated polysaccharide is inulin sulphate, most preferably inulin polysulphate sodium salt. The present invention also relates to the use of a sulphated oligosaccharide derived from a polysaccharide selected from the group consisting of inulin, gellan, pullulan, curdlan, alginic acid, laminarin, and pectin, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal.

Abstract: Substances, compositions and methods for hair treatment based on ultra-low molecular weight hyaluronic acid oligomers, possibly combined with trichogenic substances, useful for preventing hair loss and favouring its regrowth in subjects affected by androgenetic alopecia, alopecia areata, alopecia mucinosa and related disorders.

Abstract: The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable salts wherein, R is

Abstract: A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, m is 0 or 1, R1 represents a C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl group, R2 represents a hydrocarbyl group or a substituted hydrocarbyl group, and R3 and R4 represent, independently of each other, hydrogen or a chemical constituent, or either R2 and R3 together or R3 and R4 together represent a three- to seven-membered alkylene or a four- to seven-membered alkenylene bridge, for each of which at least one, preferably a CH2 group may be replaced by O, S or NR6 where R6 represents hydrogen or a hydrocarbyl group or a substituted hydrocarbyl group; or, if appropriate, an E/Z isomer and/or tautomer of the compound of formula (I), in each case in free form or in salt form.

Abstract: In a preferred embodiment, the present invention relates to a Schwannoma cell line derived from a Schwann tumor in a patient with Neurofibromatosis type 2 (NF2) and immortalized with HPV E6-E7 genes. The cell line has a unique splice site mutation of the NF2 gene. The immortalized cell line is non-tumorigenic but has altered growth properties such as higher proliferation rate and independence of Schwann cell growth factors. Methods of using this unique cell line for pharmacologic screening are disclosed.

Abstract: Compositions, apparatus, systems, kits, and methods for obfuscating the nucleic acid and/or protein content of an environment.

Abstract: The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration of cells in vivo. This fragment does not stimulate the proliferation of cells which is in contrast to activity shown by the mature, full-length 24 kDa fibroblast growth factor-2. The present invention also relates to a DNA molecule encoding the fragment, an expression vector and a transformed host containing the DNA molecule, and a method of producing the protein by culturing the transformed host. Moreover, the present invention relates to a therapeutic composition the 24 kDa fibroblast growth factor fragment and a pharmaceutically acceptable carrier.

Abstract: Provided is a pharmaceutical composition for attenuation of neuropathic pain comprising a GAD65-expressing recombinant vector. Direct introduction of the pharmaceutical composition of the present invention into a sciatic nerve leads to immediate therapeutic effects on peripheral neuropathic pain with a sustained and constant duration for several months. Therefore, the composition of the present invention is effective for the alleviation of peripheral neuropathic pain.

Abstract: The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.

Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKC activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.

Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

Abstract: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No.

Abstract: The present invention relates to oligonucleotide compositions and therapeutic uses thereof to modify protein-protein interactions.

Abstract: The present invention concerns the use of an A3 adenosine receptor agonist (A3AR agonist) for treatment of accelerated bone resorption, particularly, inflammation induced bone resorption. Specifically, there is provided by the present invention a method and pharmaceutical composition for treatment of said condition, the A3AR agonist being formulated as a pharmaceutical composition which is administered to a subject having accelerated bone resorption. The invention also provides the use of A3AR agonist in the preparation of said pharmaceutical composition.

Abstract: The present invention concerns the therapeutic treatment of inflammatory conditions by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are methods of therapeutic treatment comprising such a combined administration, pharmaceutical compositions useful in such methods comprising either an and use if either an agonist of the A3 adenosine receptor or methotrexate, as well as used of any of these active agents for preparing such a pharmaceutical composition.

Abstract: A composition for the protection, treatment and repair and for reducing the inflammation of connective tissue in mammals and a method for the treatment of connective tissue in mammals by the administration of the composition. The composition includes S-Adenosylmethionine (SAM), and a component selected from an aminosugar or salts thereof (e.g., glucosamine) or glycosaminoglycans (e.g., chondroitin salts) or mixtures or fragments thereof. The composition optionally includes manganese which promotes the production of connective tissue matrix. The composition also optionally includes methyl donors or methyl donor cofactors, such as vitamin B12, vitamin B6, folic acid, dimethylglycine or trimethylglycine.

Abstract: The present invention relates to the use of hyaluronan in protecting chondrocytes against oxidative damages and further promoting their proliferation. Particularly, the present invention relates to the use of hyaluronan with a molecular weight of 600,000-1,200,000 Dalton in protecting chondrocytes against reactive oxygen damages and further promoting their proliferation.

Abstract: A process for the isolation of low-molecular weight aminoglycan compound of formula I made up of alternating glucuronic acid and N- acetyl glucosamine units; from a hitherto unexploited natural source of waste egg shells; which process comprises the steps of: wherein M may be at one or more instances Na, Ca, K, Mg: and n is an integer between 20 and 40: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction of the low molecular weight aminoglycan compound of formula I as its water soluble salt using an aqueous polar salt solution; (c) isolation of a purified low molecular weight aminoglycan compound of formula I by gel formation out of the aqueous salt mixture by using a polar organic solvent followed by filtration or centrifuging; (d) stabilization of the isolated aminoglycan extract by sequential introduction of organic oils into a semi-dried gel to form the aminoglycan comp

Abstract: [Object] To provide a cosmetic material having a superior moisture evaporation suppression ability and a high absorbed water volume. [Solving Means] A cosmetic material contains sphingomyelin, and hence a high moisture evaporation suppression ability and a high absorbed water volume can be obtained.

Abstract: The invention concerns uses or methods for treating proliferative pathologies, in particular cancers, using ruthenium compounds and compositions containing the same. The invention also concerns novel ruthenium compounds, as well as their preparation method.

Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.

Abstract: The invention relates to methods of modulating neurite outgrowth, in culture or in a subject. The methods generally utilize cell-signaling phospholipids which interact and bind to the G protein-coupled cellular receptors (GPCRs). Such phospholipids include lysophospholipids, as well as synthetic lysophospholipid receptor agonists and antagonists that may be chemically distinct from lysophospholipids. The methods include contacting astrocytes with an effective amount of a lysophospholipid agent, and contacting neurons with the astrocytes. The methods also include treating neurons by contacting the neurons with astrocytes pretreated with a lysophospholipid agent. The methods further include contacting the neurons with an effective amount of an astrocyte-derived soluble factor (ADSF).

Abstract: Parenteral preparations of phospholipid-associated anti-inflammatories (PL-AIs) are described to treat pain/inflammation, with reduced gastrointestinal (GI) toxicity. The PL-AIs can be composed of phosphatidylcholine (“PC”) associated with non-steroidal anti-inflammatory drugs (“NSAIDs”). To prepare the PL-AIs, a phospholipid is mixed with an NSAID in a polar solvent, solvent is removed, suspended in an aqueous medium and sterilized by filtration or other acceptable method. Alternatively, the phospholipid can be mixed with an injectable preparation of an NSAID. The PL-AIs, and particularly PC associated with the NSAIDs, indomethacin, ibuprofen or diclofenac are useful for treating Patent Ductus Arteriosus in low birth weight infants to reduce the incidence of GI injury that may be manifest as Necrotizing Enterocolitis (NEC) or Spontaneous Intestinal Perforation (SIP).

Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.

Abstract: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid, e.g., corticosteroid or more specifically, a glucocorticoid.

Abstract: The invention relates to corticoid/transport protein conjugates, methods for the production thereof, and the use of the same in medicine, especially for the treatment of tumours and inflammatory processes, and for immunosuppression.

Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.

Abstract: The present invention provides a combination which comprises (a) PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors of formula (I): wherein X represents a pharmaceutically acceptable anion of a mono or polyvalent acid optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof.

Abstract: The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors and a glucocorticoid. Preferably, the combination of the PDE4 inhibitor and the glucocorticoid has a synergistic effect on apoptosis such that the level of apoptosis induced is greater than the level that would be expected by simply adding a PDE4 inhibitor to a glucocorticoid.

Abstract: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17?-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3?-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17?-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

Abstract: The present invention generally relates to methods of suppressing estrus in breeding or competitive animals comprising parenterally administering to breeding animals an estrus suppressing amount of 17-?-Allyl-17-?-hydroxyoestra-4,9,11-trien-3-one. According to the method of the present invention, estrus can be suppressed for any of a variety of periods including 30 days or more. Furthermore, the method of the present invention includes repeated sustained release doses for an indefinite period.

Abstract: The invention relates to novel crystalline forms of 3-beta-amino-17-methylene-androstane-6-alpha,7-beta-diol hydrochloride, referred to as form A, form B and form C, a method for preparing same, the use thereof as a drug, and pharmaceutical compositions containing same.

Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

Abstract: Disclosed are compounds and compositions of Formula (I) and their uses for treating Flaviviridae family virus infections.

Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

Abstract: Tetrahydropyrido[3,4-d]pyrimidines and related analogues are provided, of the formula: in which variables are as described herein, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are partially useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thrombolytic conditions.

Abstract: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.

Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated ?-amyloid deposits or ?-amyloid levels in a patient.

Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula and active compounds listed in the disclosure.

Abstract: The present invention relates to new pharmaceutical combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claims and specification, at least one further active substance 2, processes for preparing them and their use as medicaments.